Clinical Trial: TRUDI: TDXD+Durva in HER2+/Low IBC
Study Status: Completed
Recruit Status: RECRUITING
Condition: Invasive Breast Cancer
Study Type: INTERVENTIONAL
Official Title: TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer
Brief Summary:
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer.The names of the study drugs involved in this study are:Trastuzumab deruxtecanDurvalumab
Read more